Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Although patients with ECD and LCH frequently have BRAFV600 mutations and respond to BRAFV600 inhibitor therapy, there was previously a lack of data describing long-term efficacy and safety.